Company data
Adaptive Biotechnologies Corporation employees and revenue per employee
ADPT · Biotechnology · $4.52B market cap
Adaptive Biotechnologies Corporation had 624 employees at the end of fiscal Dec 2025, up 0.8% from a year earlier. Revenue for the year was $277M, up 54.8% from a year earlier, or $444K per employee. Revenue and headcount both grew, and revenue grew faster.
Employees
624
+0.8% YoY
Revenue
$277M
+54.8% YoY
Revenue / employee
$444K
Peer median $457K
Rank in industry
57 of 110
Biotechnology
Open roles
18
29 per 1,000 staff
Headcount against revenue
Both lines start at 100 in the first year we hold, so you can see which one grew faster.
Hover a year for the numbers.
| Year ending | Employees | Revenue | Per employee | Staff YoY | Revenue YoY |
|---|---|---|---|---|---|
| Dec 2025 | 624 | $277M | $444K | +0.8% | +54.8% |
| Dec 2024 | 619 | $179M | $289K | -12.7% | +5.1% |
| Dec 2023 | 709 | $170M | $240K | -10.3% | -8.1% |
| Dec 2022 | 790 | $185M | $235K | -7.9% | +20.1% |
| Dec 2021 | 858 | $154M | $180K | +37.9% | +56.9% |
| Dec 2020 | 622 | $98.4M | $158K | +37.3% | +15.6% |
| Dec 2019 | 453 | $85.1M | $188K | — | — |
Open roles on its job board: 18 (29 per 1,000 staff, against its latest annual headcount), as of 2026-11-20. Tracked since 2026-10-03. No 90 day change yet.
Adaptive Biotechnologies Corporation against similar companies
The closest industry peers by revenue, from Biotechnology.
| Company | Employees | Revenue | Revenue / employee | Shape |
|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated | 47 | $268M | $5.70M | Leaner |
| RIGL Rigel Pharmaceuticals, Inc. | 172 | $294M | $1.71M | Efficient growth |
| CRMD CorMedix Inc. | 191 | $312M | $1.63M | Efficient growth |
| ARVN Arvinas, Inc. | 246 | $263M | $1.07M | Contracting |
| VCEL Vericel Corporation | 398 | $276M | $694K | Efficient growth |
| XERS Xeris Biopharma Holdings, Inc. | 435 | $292M | $671K | Efficient growth |
| ADPT Adaptive Biotechnologies Corporation | 624 | $277M | $444K | Efficient growth |
| RCUS Arcus Biosciences, Inc. | 601 | $247M | $411K | Contracting |
| IOVA Iovance Biotherapeutics, Inc. | 975 | $264M | $270K | Efficient growth |
Questions about Adaptive Biotechnologies Corporation
- How many employees does Adaptive Biotechnologies Corporation have?
- Adaptive Biotechnologies Corporation reported 624 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 26, 2026. That is up 0.8% from a year earlier.
- What is Adaptive Biotechnologies Corporation's revenue per employee?
- Adaptive Biotechnologies Corporation brought in $277M of revenue in fiscal Dec 2025, which is $444K per employee. That ranks 57 of 110 companies we track in Biotechnology, where the median is $457K.
- Is Adaptive Biotechnologies Corporation hiring?
- Adaptive Biotechnologies Corporation's public job board listed 18 open roles on November 20, 2026, about 29 per 1,000 staff.
- Where do these numbers come from?
- Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.
Outpick research
This page is the filings. The research is a membership.
On the first and third Friday of each month Outpick publishes one stock pick with the full case for owning it, adds it to a live portfolio you can audit, and writes a note when a position closes. A new account gets 21 days of the whole membership with no card, and nothing is charged when it ends.
Free game
Think you can pick better than the S&P 500?
Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.
Enter the challengeMore data
Compare ADPT with the rest of the market
See who earns the most per employee, who is hiring, and who is cutting, across every company we track.
Source: employee counts and revenue as stated in Adaptive Biotechnologies Corporation's annual reports (Form 10-K), latest filed February 26, 2026. This is data, not a recommendation to buy or sell ADPT.